On November 9, 2023, Melinta Therapeutics LLC (Melinta) and Venatorx Pharmaceuticals, Inc. (Venatorx), announced that they have entered into a license agreement to facilitate a strategic partnership in the U.S. to commercialize cefepime-taniborbactam, a beta-lactam / beta-lactamase inhibitor (BL/BLI) combination antibiotic being developed for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in adults. The partnership follows Venatorx’s submission of a New Drug Application for cefepime-taniborbactam for the treatment of cUTI including pyelonephritis, in adults. Venatorx has been assigned a Prescription Drug User Fee Act target action date for February 22, 2024. The U.S. Food and Drug Administration granted cefepime-taniborbactam Qualified Infectious Disease Product and Fast Track designations for both the cUTI and HABP/VABP indications.

Wilson Sonsini Goodrich & Rosati advised Venatorx on IP matters related to the agreement. The Wilson Sonsini team includes Mike Hostetler, Ingo Hardt, and Celine Bonnefous.

For more information, please see the press release.